Please use this identifier to cite or link to this item: http://hdl.handle.net/10773/20069
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDuarte, I. F.pt
dc.contributor.authorLadeirinha, A. F.pt
dc.contributor.authorLamego, I.pt
dc.contributor.authorGil, A. M.pt
dc.contributor.authorCarvalho, L.pt
dc.contributor.authorCarreira, I. M.pt
dc.contributor.authorMelo, J. B.pt
dc.date.accessioned2017-12-07T19:34:24Z-
dc.date.issued2013pt
dc.identifier.issn1543-8384pt
dc.identifier.urihttp://hdl.handle.net/10773/20069-
dc.description.abstractIn this work, H-1 high resolution magic angle spinning (HRMAS) nuclear magnetic resonance (NMR) spectroscopy was used to characterize the variations in the metabolome (small metabolites and mobile lipids) of A549 human lung cells in response to exposure to the alkylating drug cisplatin. Multivariate analysis and signal integration of spectral data were carried out to unveil exposure-induced effects and follow their time course. Parallel and strongly correlated increases in lipids (particularly unsaturated triglycerides) and nucleotide sugars (particularly uridine diphosphate N-acetylglucosamine) were found in cisplatin-treated cells, highlighting these compounds as potential biomarkers of treatment response. Other significant changes upon drug exposure comprised an increase in sorbitol and decreases in niacinamide and several amino acids (glutamine, alanine, lysine, methionine, citrulline, phenylalanine and tyrosine). These results show that in vitro NMR metabolomics is a powerful tool for detecting variations in a range of intracellular compounds upon drug exposure, thus offering the possibility of identifying candidate metabolite markers for in vivo monitoring of tumor responsiveness to treatment.pt
dc.language.isoengpt
dc.publisherAMER CHEMICAL SOCpt
dc.relationinfo:eu-repo/grantAgreement/FCT/COMPETE/132936/PTpt
dc.relationinfo:eu-repo/grantAgreement/FCT/5876-PPCDTI/68017/PTpt
dc.relationinfo:eu-repo/grantAgreement/FCT/SFRH/SFRH%2FBD%2F63916%2F2009/PTpt
dc.rightsrestrictedAccesspor
dc.subjectVISIBLE MOBILE LIPIDSpt
dc.subjectCANCER CELLSpt
dc.subjectAPOPTOTIC CELLSpt
dc.subjectLEUKEMIA-CELLSpt
dc.subjectGENE-THERAPYpt
dc.subjectGLIOMA-CELLSpt
dc.subjectTUMOR-CELLSpt
dc.subjectH-1-NMRpt
dc.subjectSPECTROSCOPYpt
dc.subjectDEATHpt
dc.titlePotential Markers of Cisplatin Treatment Response Unveiled by NMR Metabolomics of Human Lung Cellspt
dc.typearticlept
dc.peerreviewedyespt
ua.distributioninternationalpt
degois.publication.firstPage4242pt
degois.publication.issue11pt
degois.publication.lastPage4251pt
degois.publication.titleMOLECULAR PHARMACEUTICSpt
degois.publication.volume10pt
dc.date.embargo10000-01-01-
dc.relation.publisherversion10.1021/mp400335kpt
dc.identifier.doi10.1021/mp400335kpt
Appears in Collections:CICECO - Artigos



FacebookTwitterLinkedIn
Formato BibTex MendeleyEndnote Degois 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.